Laith Abu-Raddad, PhD
Dr. Laith Abu-Raddad, PhD, Principal Investigator of the Infectious Disease Epidemiology Group, Professor of Healthcare Policy and Research, and Director of Biostatistics, Epidemiology and Biomathematics Research Core
Dr. Abu-Raddad is an Professor of Healthcare Policy and Research and Director of the Biostatistics and Biomathematics Research Core at WCM-Q. He focuses on studying the epidemiological factors and population processes shaping infectious disease spread in human and animal populations. He joined WCM-Q in 2008 while serving as an Assistant Professor at the Fred Hutchinson Cancer Research Center, USA. He held positions as Research Scientist at the Fred Hutchinson Cancer Research Center and the University of Washington; as Postdoctoral Research Associate at Imperial College London, United Kingdom and as NSF-JSPS Postdoctoral Research Associate at Osaka University, Japan. He completed his Ph.D. study in Computational and Mathematical Physics at Florida State University. He serves as a consultant or advisory member for a number of key public health projects for organizations such as the World Bank, Joint United Nations Programme on HIV/AIDS and World Health Organization.
Dr. Abu-Raddad's research interests are multidisciplinary with emphasis on studying the epidemiology and ecology of infectious diseases using analytical and computational approaches in addition to conventional epidemiologic study designs. He was the lead author or co-investigator of several high impact studies in recent years such as in relation to HIV/AIDS, tuberculosis, hepatitis C virus and SARS. His current main research interests include studying the spread of sexually transmitted infections such as HIV/AIDS, HSV-2 and HPV; investigating the role of biological cofactors in HIV epidemiology; assessment of the impact of different HIV interventions such as vaccines and male circumcision; studying the epidemiology of HIV/AIDS in the Arab and Muslim Worlds; studying tuberculosis epidemiology and assessing the impact of novel TB diagnostics, drug regimens and vaccines; studying the epidemiology of hepatitis C virus in the Middle East and North Africa; simulation of community randomized controlled trials and studying the ecology of multiple-strain infectious diseases.